Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
6.28
+0.24 (3.97%)
Dec 20, 2024, 4:00 PM EST - Market closed
Lexeo Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Lexeo Therapeutics stock have an average target of 23.8, with a low estimate of 19 and a high estimate of 28. The average target predicts an increase of 278.98% from the current stock price of 6.28.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 14, 2024.
Analyst Ratings
The average analyst rating for LXEO stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $21 → $23 | Strong Buy | Maintains | $21 → $23 | +266.24% | Nov 14, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $23 → $25 | Strong Buy | Maintains | $23 → $25 | +298.09% | Nov 13, 2024 |
| Leerink Partners | Leerink Partners | Buy Maintains $20 → $19 | Buy | Maintains | $20 → $19 | +202.55% | Nov 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $21 | Strong Buy | Reiterates | $21 | +234.39% | Oct 31, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $23 | Strong Buy | Maintains | $23 | +266.24% | Oct 30, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
655.72K
EPS This Year
-3.18
from -12.40
EPS Next Year
-3.07
from -3.18
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | 4.7M | n/a | |||
| Avg | n/a | 655,717 | n/a | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -3.12 | -1.88 | -1.62 | |||
| Avg | -3.18 | -3.07 | -3.18 | |||
| Low | -3.24 | -3.76 | -4.31 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.